Acute Myocardial Infarction
Conditions
Interventions
Trial Group:Roxadustat 100mg, three times a week, for 2 weeks
Standard treatment.
control group:Standard treatment
Sponsors
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged more than 18 years; 2. Diagnosed with acute ST-elevation myocardial infaction; 3. Received coronary angiography within 12 hours of symptom onset, which indicated TIMI flow 1-2 degree of the culprit vessel; 4. Received primary percutaneous coronary intervention (pPCI) within 12 hours of symptom onset, which TIMI flow after treatment is 2-3 degree. 5. Participants acknowledge the design, potential risks and benefits of this study and agree to participate in this study, and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Prior acute myocardial infarction history; 2. Already receiving or have received roxadustat treatment, or having contraindications of receiving roxadustat; 3. Cannot receive Cardiac Magnetic Resonance test; 4. Cannot receive Positron emission tomography; 5. Pregnancy or preparing to be pregnant in the term of this study; 6. Participating in other clinical trials in 30 days; 7. Other conditions that researchers decide not suitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Infact Size; | — |
Secondary
| Measure | Time frame |
|---|---|
| MACCE;Cardiac Biomarkers;LVESV;LVEF;18Ga-DOTATATE intake; | — |
Countries
China
Contacts
Public ContactRuiyan Zhang
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
Outcome results
None listed